Marshall Wace, LLP Kura Oncology, Inc. Transaction History
Marshall Wace, LLP
- $81.7 Billion
- Q2 2025
A detailed history of Marshall Wace, LLP transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 42,363 shares of KURA stock, worth $262,650. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,363
Previous 392,049
89.19%
Holding current value
$262,650
Previous $2.59 Million
90.57%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding KURA
# of Institutions
189Shares Held
79.5MCall Options Held
53.6KPut Options Held
42.8K-
Suvretta Capital Management, LLC New York, NY8.12MShares$50.3 Million1.61% of portfolio
-
Bvf Inc San Francisco, CA7.75MShares$48.1 Million1.76% of portfolio
-
Black Rock Inc. New York, NY6.97MShares$43.2 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY6.2MShares$38.4 Million0.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.35MShares$33.2 Million0.0% of portfolio
About Kura Oncology, Inc.
- Ticker KURA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,893,000
- Market Cap $415M
- Description
- Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...